The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROLE OF BRAIN SEROTONIN IN RESERPINE ACTION
Shore, P. A., Pletscher, A., Tomich, E. G., Carlsson, A., Kuntzman, R., & Brodie, B. B. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40751.x · Cited by 173
Self-citationBIOCHEMICAL FINDINGS RELATING TO THE ACTION OF SEROTONIN
Udenfriend, S., Weissbach, H., & Bogdanski, D. F. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40750.x · Cited by 140
Cited by
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
The validity of animal models of depression
Willner, P. (1984) · Psychopharmacology · doi:10.1007/bf00427414 · Cited by 1,409
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Norepinephrine in Depressive Reactions: A Review
BUNNEY, W. E. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01730060001001 · Cited by 1,153
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Description of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
Schildkraut, J. J., & Kety, S. S. (1967) · Science · doi:10.1126/science.156.3771.21 · Cited by 875
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
Dopaminergic modulation of synaptic transmission in cortex and striatum
Tritsch, N. X., & Sabatini, B. L. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.023 · Cited by 756
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Benitez-Temino, B., Blesa, F. J., Guridi, J., Marin, C., & Rodriguez, M. (2008) · Movement Disorders · doi:10.1002/mds.22062 · Cited by 663
Diagnosis and treatment of Parkinson disease: molecules to medicine
Savitt, J. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29178 · Cited by 650
On the Presence of 3-Hydroxytyramine in Brain
CARLSSON, A., LINDQVIST, M., MAGNUSSON, T., & WALDECK, B. (1958) · Science · doi:10.1126/science.127.3296.471 · Cited by 634
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Gerlach, M., & Riederer, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 498
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Cerebral Activity and Behavior: Control by Central Cholinergic and Serotonergic Systems
Vanderwolf, C. H. (1988) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60050-1 · Cited by 455
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Neurotransmitter and psychostimulant recognition by the dopamine transporter
Wang, K. H., Penmatsa, A., & Gouaux, E. (2015) · Nature · doi:10.1038/nature14431 · Cited by 425
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Noradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 414
Carlsson, A., Fuxe, K., Hamberger, B., & Lindqvist, M. (1966) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1966.tb03334.x · Cited by 412
Self-citationReticulo-cortical activity and behavior: A critique of the arousal theory and a new synthesis
Vanderwolf, C. H., & Robinson, T. E. (1981) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00009869 · Cited by 411
Taverna, S., Ilijic, E., & Surmeier, D. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5493-07.2008 · Cited by 399
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Conducting polymer-based electrochemical biosensors for neurotransmitters: A review
Moon, J.-M., Thapliyal, N., Hussain, K. K., Goyal, R. N., & Shim, Y.-B. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.11.069 · Cited by 390
Cyclic and Sleep-Like Spontaneous Alternations of Brain State Under Urethane Anaesthesia
Clement, E. A., Richard, A., Thwaites, M., Ailon, J., Peters, S., & Dickson, C. T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002004 · Cited by 349
The Yin and Yang of dopamine release: a new perspective
GOTO, Y., OTANI, S., & GRACE, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.007 · Cited by 342
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
Fahn, S. (2008) · Movement Disorders · doi:10.1002/mds.22028 · Cited by 339
Biosensors and sensors for dopamine detection
Liu, X., & Liu, J. (2021) · VIEW · doi:10.1002/viw.20200102 · Cited by 329
Sun, C.-L., Chang, C.-T., Lee, H.-H., Zhou, J., Wang, J., Sham, T.-K., & Pong, W.-F. (2011) · ACS Nano · doi:10.1021/nn2015908 · Cited by 328
Einhorn, L., Johansen, P., & White, F. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-01-00100.1988 · Cited by 312
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 295
Drugs which block the storage of 5-hydroxytryptamine and related amines
Carlsson, A. (1966) · 5-Hydroxytryptamine and Related Indolealkylamines · doi:10.1007/978-3-642-85467-5_11 · Cited by 291
Self-citationLevodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
NEUROLOGICAL SYMPTOMS IN PHARMAGOTHERAPY OF PSYCHOSES
Faurbye, A., Rasch, P. ‐., Petersen, P. B., &, G. B., & Pakkenberg, H. (1964) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1964.tb05731.x · Cited by 262
Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine
Stadler, H., Lloyd, K. G., Gadea-Ciria, M., & Bartholini, G. (1973) · Brain Research · doi:10.1016/0006-8993(73)90317-x · Cited by 261
Regular Induction of Hypomania by L-Dopa in “Bipolar” Manic-depressive Patients
MURPHY, D. L., BRODIE, H. K. H., GOODWIN, F. K., & BUNNEY, W. E. (1971) · Nature · doi:10.1038/229135a0 · Cited by 257
Dopaminergic basis of salience dysregulation in psychosis
Winton-Brown, T. T., Fusar-Poli, P., Ungless, M. A., & Howes, O. D. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.003 · Cited by 231
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
Thanvi, B. R., & Lo, T. C. N. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.013912 · Cited by 194
Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse
Willuhn, I., Wanat, M. J., Clark, J. J., & Phillips, P. E. M. (2010) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2009_27 · Cited by 193
Phasic dopamine release in appetitive behaviors and drug addiction
Wanat, M., Willuhn, I., Clark, J., & Phillips, P. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902020195 · Cited by 177
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Braslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Structural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2024) · eLife · doi:10.7554/elife.91973.4 · Cited by 14
Scalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Structural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2023) · doi:10.1101/2023.09.05.556211 · Cited by 6
Structural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2024) · doi:10.7554/elife.91973.3
Metadata
- Authors
- CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T.
- Venue
- Nature
- Published
- 1957-11-30
- Volume
- 180
- Issue
- 4596
- Pages
- 1200-1200
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2085518524
- Cited by
- 1,278
- References
- 2
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.